Research & Studies
Share your love
Novartis to Halt Development of GA Gene Therapy
After observing discouraging phase 2 clinical data, Novartis has opted to terminate the clinical advancement of its geographic atrophy gene therapy candidate GT005, a product it acquired through the acquisition of Gyroscope Therapeutics. The announcement was officially disseminated by investment…
What Is Bull’s Eye Maculopathy and How to Manage It
What Is Bull’s Eye Maculopathy? Bull’s Eye Maculopathy is a specific form of retinal disease characterized by changes in the pigmentation of the macular region of the retina, often presenting as a ‘bull’s eye’ pattern. The macula is the central…
Iveric Bio’s Izervay for Geographic Atrophy Approved by FDA
Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…
Best Treatment for Uveitic Macular Edema Identified
Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…
Study Unveils the Dynamic Architecture of the Human Eye
The retinal pigment epithelium (RPE) and choroid, located behind the human retina, play crucial roles in vision, encompassing functions such as light absorption and providing oxygenated blood to photoreceptor cells. However, our current understanding of gene expressions within these cells…
Aegis and Northwell Launch AI Company Optain
Ascertain, a joint venture between Aegis Ventures and Northwell Holdings, has raised $12 million in seed funding to launch Optain, an AI company that utilizes retinal imaging for early disease detection and prevention. Optain’s AI technology analyzes data from a…
Naegis Pharma Funds Novel Eye Drug
Naegis Pharmaceuticals Inc., a life sciences company specializing in inflammation and ophthalmology, announced the successful closure of a financing round to advance its lead compound, N0651, towards a Phase 2 clinical trial. This funding will support the compound’s progression through…
2023 Recap: Top 10 Contact Lenses and Technologies
In the ever-evolving landscape of ophthalmology, 2023 has proven to be a year of groundbreaking advancements in contact lens technology. From lenses that adapt to UV and temperature changes to intelligent lenses capable of diagnosing and treating glaucoma, the top…
Glaucoma Patients Miss Regular Eye Doctor Visits
In the August issue of Ophthalmology Epidemiology, a recently published study unveils a concerning trend among glaucoma patients. It was discovered that one-third of these patients ceased to visit their eye doctors for regular check-ups over a 10-year period. Conducted…
Glaucomatous Optic Neuropathy & Latest Treatments
Glaucomatous optic neuropathy is characterized by progressive loss of retinal ganglion cells (RGCs) and their axons and leads to measureable structural and functional damage to the optic nerve, visual impairment, and blindness. The primary site of injury is thought to be…